

Patent Application
Attorney Docket No. 5771-P1-01-MG
PC17351

Applicants herein above include a clean version of the amended claims and a "Version with Markings to Show Changes Made" and apologize for their earlier oversight.

Applicants request an early examination and allowance of the application.

Respectfully submitted,

Date:

10/24/2002


A. Dean Olson
Attorney for Applicant(s)
Reg. No. 31,185

Pfizer Inc.
Patent Department, MS8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-4904

VERSION WITH MARKINGS TO SHOW CHANGES MADE
IN THE SPECIFICATION

CLAIMS

Please amend claim 1 as follows:

1. (Amended) A method of treating or preventing sexual dysfunction which comprises administering to a subject suffering or liable to suffer therefrom and in need of treatment or prevention an effective amount of a bombesin receptor antagonist.

Claims 2 – 3 are cancelled.

Claims 11 - 13 are cancelled.

Please amend Claim 14 as follows:

14. (Amended) The method of claim 22 1, wherein the vasodilator is the bombesin receptor antagonist is administered in combination with selected from alprostadil or phentolamine.

Claim 15 is cancelled.

Please amend Claim 16 as follows:

16. (Amended) The method of claim 22 1, wherein the bombesin receptor antagonist is administered in combination with vasodilator is a compound that promotes production of NO.

Please amend Claim 21 as follows:

21. The method of claim 44 1, wherein the bombesin receptor antagonist and the a vasodilator are simultaneously administered to the subject in the form of a composition

containing a unit dose of the bombesin receptor antagonist, a unit dose of the vasodilator and a pharmaceutically acceptable carrier or diluent.

Please add new Claims 24-46:

-- 24. (New) The method of claim 5, wherein the sexual dysfunction is hypoactive sexual desire disorder.

25. (New) The method of claim 5, wherein the sexual dysfunction is a sexual arousal disorder.

26. (New) The method of claim 5, wherein the sexual dysfunction is an orgasmic disorder or anorgasmia.

27. (New) The method of claim 5, wherein the sexual dysfunction is sexual pain disorder.

28. (New) The method of claim 5, wherein the subject is receiving an antidepressant or antihypertensive.

29. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a vasodilator which acts on local blood flow at the clitoris or vagina or on lubricant secretion.

30. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a PDE5 inhibitor.

31. (New) The method of claim 30, wherein the PDE5 inhibitor is sildenafil or a pharmaceutically acceptable salt thereof.

32. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a VIP enhancer.

33. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an angiotensin-2 receptor.

34. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an oestrogen.

35. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an androgen.

36. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a neurotransmitter modulator.

37. (New) The method of claim 6, wherein the sexual dysfunction is erectile dysfunction.

38. (New) The method of claim 6, wherein the sexual dysfunction is psychogenic.

39. (New) The method of claim 6, wherein the sexual dysfunction is drug-induced.

40. (New) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a vasodilator which acts on local blood flow at the penis.

41. (New) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a PDE5 inhibitor.

42. (New) The method of claim 6, wherein the PDE5 inhibitor is sildenafil or a pharmaceutically acceptable salt thereof.

43. (New) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a VIP enhancer.

44. (New) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with an angiotensin-2 receptor.

45. (New) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with an androgen.

46. (New) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a neurotransmitter modulator. --